Asset Management One Co. Ltd. Has $23.46 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Asset Management One Co. Ltd. boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 55,872 shares of the company's stock after purchasing an additional 3,028 shares during the period. Asset Management One Co. Ltd. owned approximately 0.07% of IDEXX Laboratories worth $23,463,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of IDEXX Laboratories in the first quarter valued at $992,000. Vantage Investment Partners LLC bought a new position in shares of IDEXX Laboratories in the first quarter valued at $22,348,000. Center For Asset Management LLC bought a new position in shares of IDEXX Laboratories in the first quarter valued at $226,000. Suncoast Equity Management increased its holdings in shares of IDEXX Laboratories by 16.6% in the first quarter. Suncoast Equity Management now owns 1,777 shares of the company's stock valued at $746,000 after buying an additional 253 shares in the last quarter. Finally, World Equity Group Inc. bought a new position in shares of IDEXX Laboratories in the first quarter valued at $247,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IDXX has been the topic of several research reports. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Leerink Partners boosted their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Finally, Stifel Nicolaus boosted their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday, May 19th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $546.00.

IDEXX Laboratories Stock Up 0.7%

Shares of IDEXX Laboratories stock traded up $3.54 on Friday, hitting $531.32. 624,759 shares of the company traded hands, compared to its average volume of 645,765. The company has a 50-day moving average price of $499.01 and a 200 day moving average price of $450.94. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $535.20. The company has a market cap of $42.73 billion, a PE ratio of 49.11, a PEG ratio of 3.88 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same period in the previous year, the company posted $2.71 EPS. IDEXX Laboratories's revenue was up 3.6% on a year-over-year basis. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Activity

In related news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director now directly owns 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.